{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T17:41:28Z","timestamp":1787161288979,"version":"build-2736575974"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-026-04752-y","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T04:53:15Z","timestamp":1787115195000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Combined use of SGLT2 inhibitor and GLP-1 receptor agonist versus either monotherapy for cardiorenal Outcomes: an exploratory network meta-analysis of 16 randomized trials"],"prefix":"10.1007","volume":"91","author":[{"given":"Mainak","family":"Banerjee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhurima","family":"Basu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pradip","family":"Mukhopadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujoy","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"issue":"4","key":"4752_CR1","doi-asserted-by":"publisher","first-page":"531","DOI":"10.2337\/dci23-0041","volume":"47","author":"N Sattar","year":"2024","unstructured":"N. Sattar, C. Presslie, M.K. Rutter, D.K. McGuire, Cardiovascular and Kidney Risks in Individuals With Type 2 Diabetes: Contemporary Understanding With Greater Emphasis on Excess Adiposity. Diabetes Care. 47(4), 531\u2013543 (2024). https:\/\/diabetesjournals.org\/care\/article\/47\/4\/531\/154299\/Cardiovascular-and-Kidney-Risks-in-Individuals","journal-title":"Diabetes Care"},{"issue":"Supplement1","key":"4752_CR2","first-page":"S181","volume":"48","author":"NA Committee","year":"2025","unstructured":"American Diabetes Association Professional Practice, N.A. Committee, R.G. ElSayed, G. McCoy, M. Aleppo, K. Bajaj, Balapattabi et al., 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes\u20142025. Diabetes Care. 48(Supplement1), S181\u2013206 (2025). https:\/\/diabetesjournals.org\/care\/article\/48\/Supplement_1\/S181\/157569\/9-Pharmacologic-Approaches-to-Glycemic-Treatment","journal-title":"Diabetes Care"},{"issue":"2","key":"4752_CR3","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1111\/dom.16077","volume":"27","author":"C Vale","year":"2025","unstructured":"C. Vale, I.M. Louren\u00e7o, G. Jordan, I. Golovaty, H. Torres, T. Moin et al., Early combination therapy with SGLT2i and GLP -1 RA or dual GIP \/ GLP \u20101 RA in type 2 diabetes. Diabetes Obesity Metabolism. 27(2), 468\u201381 (2025). https:\/\/doi.org\/10.1111\/dom.16077","journal-title":"Diabetes Obesity Metabolism"},{"issue":"1","key":"4752_CR4","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s00125-025-06565-6","volume":"69","author":"JMT Colombijn","year":"2026","unstructured":"J.M.T. Colombijn, J.F. De, F.L.J. Leijer, M.C. Visseren, D.H. Verhaar, Van, N. Raalte, Sattar et al., Effectiveness and safety of combining SGLT2 inhibitors and GLP-1 receptor agonists in individuals with type 2 diabetes: a systematic review and meta-analysis of cohort studies. Diabetologia. 69(1), 36\u201349 (2026). https:\/\/doi.org\/10.1007\/s00125-025-06565-6","journal-title":"Diabetologia"},{"issue":"1","key":"4752_CR5","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1186\/s12933-025-02900-8","volume":"24","author":"A Shokravi","year":"2025","unstructured":"A. Shokravi, J. Seth, G.B.J. Mancini, Cardiovascular and renal outcomes of dual combination therapies with glucagon-like peptide-1 receptor agonists and sodium-glucose transport protein 2 inhibitors: a systematic review and meta-analysis. Cardiovasc. Diabetol. 24(1), 370 (2025). https:\/\/doi.org\/10.1186\/s12933-025-02900-8","journal-title":"Cardiovasc. Diabetol."},{"issue":"8","key":"4752_CR6","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S2213-8587(24)00155-4","volume":"12","author":"EM Apperloo","year":"2024","unstructured":"E.M. Apperloo, B.L. Neuen, R.A. Fletcher, N. Jongs, S.D. Anker, D.L. Bhatt et al., Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials. The Lancet Diabetes & Endocrinology. 12(8), 545\u201357 (2024). https:\/\/doi.org\/10.1016\/S2213-8587(24)00155-4","journal-title":"The Lancet Diabetes & Endocrinology"},{"issue":"22","key":"4752_CR7","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1161\/CIRCULATIONAHA.124.071689","volume":"150","author":"BL Neuen","year":"2024","unstructured":"B.L. Neuen, R.A. Fletcher, L. Heath, A. Perkovic, M. Vaduganathan, S.V. Badve et al., Cardiovascular, Kidney, and Safety Outcomes With GLP-1 Receptor Agonists Alone and in Combination With SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Review and Meta-Analysis. Circulation. 150(22), 1781\u20131790 (2024). https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.124.071689","journal-title":"Circulation"},{"issue":"11","key":"4752_CR8","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"B. Hutton, G. Salanti, D.M. Caldwell, A. Chaimani, C.H. Schmid, C. Cameron et al., The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations. Ann Intern Med. 162(11), 777\u201384.(2015) https:\/\/doi.prg\/10.7326\/M14-2385","journal-title":"Ann Intern Med"},{"key":"4752_CR9","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"J.A.C. Sterne, J. Savovi\u0107, M.J. Page, R.G. Elbers, N.S. Blencowe, I. Boutron et al., RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 366, l4898 (2019). https:\/\/doi.org\/10.1136\/bmj.l4898","journal-title":"BMJ"},{"issue":"9","key":"4752_CR10","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1002\/sim.1761","volume":"23","author":"J Sweeting","year":"2004","unstructured":"J. Sweeting, M.J. Sutton, A.C. Lambert, What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat. Med. 23(9), 1351\u20131375 (2004). https:\/\/doi.org\/10.1002\/sim.1761","journal-title":"Stat. Med."},{"issue":"14","key":"4752_CR11","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1002\/sim.3594","volume":"28","author":"NJ Cooper","year":"2009","unstructured":"N.J. Cooper, A.J. Sutton, D. Morris, A.E. Ades, N.J. Welton, Addressing between-study heterogeneity and inconsistency in mixed treatment comparisons: Application to stroke prevention treatments in individuals with non\u2010rheumatic atrial fibrillation. Stat. Med. 28(14), 1861\u20131881 (2009). https:\/\/doi.org\/10.1002\/sim.3594","journal-title":"Stat. Med."},{"issue":"4","key":"4752_CR12","doi-asserted-by":"publisher","first-page":"e1003082","DOI":"10.1371\/journal.pmed.1003082","volume":"17","author":"A Nikolakopoulou","year":"2020","unstructured":"A. Nikolakopoulou, J.P.T. Higgins, T. Papakonstantinou, A. Chaimani, D.C. Giovane, M. Egger et al., CINeMA: An approach for assessing confidence in the results of a network meta-analysis. PLoS Med. 17(4), e1003082 (2020). https:\/\/doi.org\/10.1371\/journal.pmed.1003082","journal-title":"PLoS Med."},{"issue":"1","key":"4752_CR13","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1186\/s12916-021-02166-3","volume":"19","author":"V Chiocchia","year":"2021","unstructured":"V. Chiocchia, A. Nikolakopoulou, J.P.T. Higgins, M.J. Page, T. Papakonstantinou, A. Cipriani et al., ROB-MEN: a tool to assess risk of bias due to missing evidence in network meta-analysis. BMC Med. 19(1), 304 (2021). https:\/\/doi.org\/10.1186\/s12916-021-02166-3","journal-title":"BMC Med."},{"issue":"22","key":"4752_CR14","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"B. Zinman, C. Wanner, J.M. Lachin, D. Fitchett, E. Bluhmki, S. Hantel et al., Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl. J. Med. 373(22), 2117\u20132128 (2015). https:\/\/doi.org\/10.1056\/NEJMoa1504720","journal-title":"N Engl. J. Med."},{"issue":"7","key":"4752_CR15","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"B. Neal, V. Perkovic, K.W. Mahaffey, D. Zeeuw, G. Fulcher, N. Erondu et al., Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl. J. Med. 377(7), 644\u2013657 (2017). https:\/\/doi.org\/10.1056\/NEJMoa1611925","journal-title":"N Engl. J. Med."},{"issue":"4","key":"4752_CR16","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"S.D. Wiviott, I. Raz, M.P. Bonaca, O. Mosenzon, E.T. Kato, A. Cahn et al., Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl. J. Med. 380(4), 347\u2013357 (2019). https:\/\/doi.org\/10.1056\/NEJMoa1812389","journal-title":"N Engl. J. Med."},{"issue":"15","key":"4752_CR17","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","volume":"383","author":"CP Cannon","year":"2020","unstructured":"C.P. Cannon, R. Pratley, S. Dagogo-Jack, J. Mancuso, S. Huyck, U. Masiukiewicz et al., Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. N Engl. J. Med. 383(15), 1425\u20131435 (2020). https:\/\/doi.org\/10.1056\/NEJMoa2004967","journal-title":"N Engl. J. Med."},{"issue":"2","key":"4752_CR18","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1056\/NEJMoa2030186","volume":"384","author":"DL Bhatt","year":"2021","unstructured":"D.L. Bhatt, M. Szarek, B. Pitt, C.P. Cannon, L.A. Leiter, D.K. McGuire et al., Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. N Engl. J. Med. 384(2), 129\u2013139 (2021). https:\/\/doi.org\/10.1056\/NEJMoa2030186","journal-title":"N Engl. J. Med."},{"issue":"24","key":"4752_CR19","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"V. Perkovic, M.J. Jardine, B. Neal, S. Bompoint, H.J.L. Heerspink, D.M. Charytan et al., Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl. J. Med. 380(24), 2295\u20132306 (2019). https:\/\/doi.org\/10.1056\/NEJMoa1811744","journal-title":"N Engl. J. Med."},{"issue":"21","key":"4752_CR20","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"J.J.V. McMurray, S.D. Solomon, S.E. Inzucchi, L. K\u00f8ber, M.N. Kosiborod, F.A. Martinez et al., Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl. J. Med. 381(21), 1995\u20132008 (2019). https:\/\/doi.org\/10.1056\/NEJMoa1911303","journal-title":"N Engl. J. Med."},{"issue":"15","key":"4752_CR21","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"H.J.L. Heerspink, B.V. Stef\u00e1nsson, R. Correa-Rotter, G.M. Chertow, T. Greene, F.F. Hou et al., Dapagliflozin in Patients with Chronic Kidney Disease. N Engl. J. Med. 383(15), 1436\u20131446 (2020). https:\/\/doi.org\/10.1056\/NEJMoa2024816","journal-title":"N Engl. J. Med."},{"issue":"15","key":"4752_CR22","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"M. Packer, S.D. Anker, J. Butler, G. Filippatos, S.J. Pocock, P. Carson et al., Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl. J. Med. 383(15), 1413\u20131424 (2020). https:\/\/doi.org\/10.1056\/NEJMoa2022190","journal-title":"N Engl. J. Med."},{"issue":"16","key":"4752_CR23","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"S.D. Anker, J. Butler, G. Filippatos, J.P. Ferreira, E. Bocchi, M. B\u00f6hm et al., Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl. J. Med. 385(16), 1451\u20131461 (2021). https:\/\/doi.org\/10.1056\/NEJMoa2107038","journal-title":"N Engl. J. Med."},{"issue":"12","key":"4752_CR24","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","volume":"387","author":"SD de Solomon","year":"2022","unstructured":"S.D. Solomon, J.J.V. McMurray, B. Claggett, de R.A. Boer, D. DeMets, A.F. Hernandez et al., Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl. J. Med. 387(12), 1089\u20131098 (2022). . https:\/\/doi.org\/10.1056\/NEJMoa2206286","journal-title":"N Engl. J. Med."},{"key":"4752_CR25","doi-asserted-by":"publisher","unstructured":"The EMPA-KIDNEY Collaborative Group. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med [Internet], 2022 Nov 4 [cited 2022 Nov 6];NEJMoa2204233. Available from: http:\/\/www.nejm.org\/doi\/https:\/\/doi.org\/10.1056\/NEJMoa2204233","DOI":"10.1056\/NEJMoa2204233"},{"issue":"8","key":"4752_CR26","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1161\/CIRCULATIONAHA","volume":"145","author":"CSP Lam","year":"2022","unstructured":"C.S.P. Lam, C. Ramasundarahettige, K.R.H. Branch, N. Sattar, J. Rosenstock, R. Pratley et al., Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial. Circulation. 145(8), 565\u2013574 (2022). https:\/\/doi.org\/10.1161\/CIRCULATIONAHA","journal-title":"Circulation"},{"issue":"6","key":"4752_CR27","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.jacc.2023.05.048","volume":"82","author":"JS Neves","year":"2023","unstructured":"J.S. Neves, M. Borges-Canha, F. Vasques-N\u00f3voa, J.B. Green, L.A. Leiter, C.B. Granger et al., GLP-1 Receptor Agonist Therapy With and Without SGLT2 Inhibitors in Patients With Type 2 Diabetes. J. Am. Coll. Cardiol. 82(6), 517\u2013525 (2023). https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S073510972305876X","journal-title":"J. Am. Coll. Cardiol."},{"issue":"10","key":"4752_CR28","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1038\/s41591-024-03133-0","volume":"30","author":"JFE Mann","year":"2024","unstructured":"J.F.E. Mann, P. Rossing, G. Bakris, N. Belmar, H. Bosch-Traberg, R. Busch et al., Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial. Nat. Med. 30(10), 2849\u20132856 (2024). https:\/\/www.nature.com\/articles\/s41591-024-03133-0","journal-title":"Nat. Med."},{"issue":"23","key":"4752_CR29","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1161\/CIRCULATIONAHA","volume":"551","author":"N Marx","year":"2025","unstructured":"N. Marx, J.E. Deanfield, J.F.E. Mann, R. Arechavaleta, S.C. Bain, H.S. Bajaj et al., Oral Semaglutide and Cardiovascular Outcomes in Persons With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial. Circulation. 151(23):1639-50 (2025). https:\/\/doi.org\/10.1161\/CIRCULATIONAHA","journal-title":"Circulation"},{"issue":"6","key":"4752_CR30","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.jacc.2023.06.005","volume":"82","author":"VR Aroda","year":"2023","unstructured":"V.R. Aroda, L.K. Billings, GLP-1 RA and SGLT2 Inhibitors. J. Am. Coll. Cardiol. 82(6), 526\u2013528 (2023). https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109723058771","journal-title":"J. Am. Coll. Cardiol."},{"issue":"3","key":"4752_CR31","doi-asserted-by":"publisher","first-page":"109","DOI":"10.4103\/2229-3485.83221","volume":"2","author":"S Gupta","year":"2011","unstructured":"S. Gupta, Intention-to-treat concept: A review. Perspect. Clin. Res. 2(3), 109 (2011). https:\/\/doi.org\/10.4103\/2229-3485.83221","journal-title":"Perspect. Clin. Res."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-026-04752-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-026-04752-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-026-04752-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T17:02:21Z","timestamp":1787158941000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-026-04752-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,19]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4752"],"URL":"https:\/\/doi.org\/10.1007\/s12020-026-04752-y","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,19]]},"assertion":[{"value":"3 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"281"}}